Abivax to present blood and rectal tissue data from UC patients treated with obefazimod at the 18th Congress of ECCO
Abivax will be presenting a poster on blood and rectal tissue data from ulcerative colitis (UC) patients, confirming the novel mechanism of action of obefazimod based on the upregulation of a single microRNA, miR-124
The presentation will be given at the 18th Congress of ECCO during the poster session taking place on March 3, 2023, at 12:30-1:30pm CET by Julien Santo, Ph.D., Director of Translational Research at Abivax and principal author of the abstract
PARIS, France, February 14, 2023 – 06:00 p.m. (CET) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, today announced that its scientific abstract has been selected for a poster presentation at the 18th Congress of ECCO taking place on March 1-4, 2023, in Copenhagen, Denmark. The abstract is entitled: “Obefazimod upregulates miR-124 and downregulates the expression of some cytokines in blood and rectal biopsies of patients with moderate-to-severe ulcerative colitis.”
The Congress of ECCO is one of the world’s leading conferences focused on Inflammatory Bowel Diseases (IBD), such as ulcerative colitis and Crohn’s disease.
Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax, said: “After the recent publication of the data in the journal Clinical and Translational Gastroenterology, we are excited by the selection of our abstract for a poster presentation at the ECCO Congress. We believe the blood and biopsy data validates and extends obefazimod’s novel and potent anti-inflammatory mechanism of action. It complements our scientific findings released on our clinical Phase 2a and Phase 2b induction and maintenance results that were generated with obefazimod for the treatment of patients with moderate to severe ulcerative colitis. The scientific publication and the selection of the abstract show the increasing interest of the scientific community with respect to the novel mechanism of action of our lead molecule and its potential to efficiently, durably and safely treat UC patients.”
Abivax Poster Presentation at the 18th Congress of ECCO
Session date: Friday, March 3, 2023
Session name: Guided Poster Session
Presentation number: P001
Session time: 12:30 - 1:30pm CET
Session hall: Poster Exhibition, Hall B5&6
Presenter: Julien Santo, Ph.D., Director of Translational Research at Abivax
Abivax recently published a scientific article, highlighting obefazimod’s novel mechanism of action and its capacity to treat patients with moderate to severe UC, in the peer-reviewed journal Clinical and Translational Gastroenterology (CTG) entitled: “ABX464 (obefazimod) up-regulates miR-124 to reduce pro-inflammatory markers in inflammatory bowel diseases.” 1
*****
About Abivax (www.abivax.com)
Abivax is a Phase 3 clinical stage biotechnology company, focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases. Abivax, founded by Truffle Capital, is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of ulcerative colitis. More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_.
Contacts
|
Abivax |
Investors |
Press Relations & Investors Europe |
|
Public Relations France |
Public Relations France |
Public Relations USA |
DISCLAIMER
This press release contains forward-looking statements, forecasts and estimates (including patient recruitment) with respect to certain of Abivax’s programs. Although Abivax’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks, contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of Abivax, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. A description of these risks, contingencies and uncertainties can be found in the documents filed by Abivax with the French Autorité des Marchés Financiers pursuant to its legal obligations including its registration document (Document d’Enregistrement Universel). These risks, contingencies and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates. Special consideration should be given to the potential hurdles of clinical and pharmaceutical development including further assessment by the company and regulatory agencies and IRBs/ethics committees following the assessment of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data. Furthermore, these forward-looking statements, forecasts and estimates are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that Abivax becomes aware of, except as required by law. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement. This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe securities of Abivax in any jurisdiction, in particular in France. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgement. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.
1 Apolit et al.: ABX464 (obefazimod) up-regulates miR-124 to reduce pro-inflammatory markers in inflammatory bowel diseases, CTG, published online Jan. 2023.